- Home
- VTEX vs ABUS Comparison
VTEX vs ABUS Comparison
Compare VTEX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTEX
- ABUS
- Stock Information
- Founded
- VTEX 1999
- ABUS 2005
- Country
- VTEX Cayman Islands
- ABUS United States
- Employees
- VTEX N/A
- ABUS 44
- Industry
- VTEX Computer Software: Prepackaged Software
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- VTEX Technology
- ABUS Health Care
- Exchange
- VTEX Nasdaq
- ABUS Nasdaq
- Market Cap
- VTEX 710.7M
- ABUS 828.9M
- IPO Year
- VTEX 2021
- ABUS N/A
- Fundamental
- Price
- VTEX $3.84
- ABUS $4.34
- Analyst Decision
- VTEX Strong Buy
- ABUS Strong Buy
- Analyst Count
- VTEX 5
- ABUS 2
- Target Price
- VTEX $6.96
- ABUS $5.00
- AVG Volume (30 Days)
- VTEX 1.9M
- ABUS 1.1M
- Earning Date
- VTEX 11-06-2025
- ABUS 11-13-2025
- Dividend Yield
- VTEX N/A
- ABUS N/A
- EPS Growth
- VTEX 8.40
- ABUS N/A
- EPS
- VTEX 0.07
- ABUS N/A
- Revenue
- VTEX $234,115,000.00
- ABUS $14,606,000.00
- Revenue This Year
- VTEX $8.95
- ABUS $138.02
- Revenue Next Year
- VTEX $12.64
- ABUS N/A
- P/E Ratio
- VTEX $54.49
- ABUS N/A
- Revenue Growth
- VTEX 3.65
- ABUS 116.64
- 52 Week Low
- VTEX $3.65
- ABUS $2.71
- 52 Week High
- VTEX $6.93
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- VTEX 38.56
- ABUS 45.67
- Support Level
- VTEX $3.72
- ABUS $4.08
- Resistance Level
- VTEX $3.92
- ABUS $4.87
- Average True Range (ATR)
- VTEX 0.21
- ABUS 0.23
- MACD
- VTEX -0.03
- ABUS -0.05
- Stochastic Oscillator
- VTEX 20.56
- ABUS 32.28
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.